GlaxoSmythKline recently conducted safety trial studies on their new experimental Genital Herpes vaccine ‘Simplirix’. 8,323 women aged 18-30 years participated in the trial at 50 sites in the US & Canada. Based on the results the product has failed miserably. The question is why were these women infected with Herpes after vaccination with the virus? If they weren’t sexually active at the time or involved with partners already infected a class action Lawsuit against GSK should logically ensue.
“The estimate of vaccine effectiveness was 20 percent, but all estimates have statistical uncertainty, and this effect was not substantially different from zero.” National Institute of Health
NATIONAL INSTITUTES OF HEALTH STATEMENT
Study Finds Genital Herpes Vaccine Ineffective in Women –
‘An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women. The Phase 3 trial, sponsored by GlaxoSmithKline (GSK) Biologicals, based in Belgium, with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, began in 2002. A total of 8,323 women aged 18-30 years participated in the trial at 50 sites in the United States and Canada. At the time of their enrollment, the study participants were free of the two types of herpes simplex viruses (HSV), HSV-1 + HSV-2.
Participants in the Herpevac trial were randomly divided into two groups. One group received the candidate vaccine, containing HSV protein along with an adjuvant intended to boost immune responses. The second, control group received a version of Havrix, a licensed vaccine against hepatitis A. This study design gave all participants the potential opportunity to be protected against either genital herpes or hepatitis A. GSK developed the candidate vaccine; also manufactures Havrix.
Each volunteer was vaccinated at the beginning of the study and again one and six months later. The participants were followed for 20 months after the initial injection and evaluated at each visit for HSV infection and genital herpes disease.
In two earlier studies involving men and women who did not have genital herpes but whose sexual partners were known to be infected, the candidate vaccine prevented genital herpes disease in more than 70 percent of the female volunteers who were free of HSV-1 and HSV-2 but had no clear effect in men. These studies formed the basis to conduct the larger Herpevac study in women only.
In the Herpevac study, however, the investigational vaccine was ineffective in protecting against genital herpes disease. The estimate of vaccine effectiveness was 20 percent, but all estimates have statistical uncertainty, and this effect was not substantially different from zero.
It is not known at this time why the vaccine proved ineffective, but the study collaborators continue to evaluate the trial data and intend to provide a more detailed analysis at a later date. All the study investigators have been informed of the results. Study participants are being notified as to which vaccine they received, and those volunteers who received the candidate herpes vaccine are being offered Havrix.’
GSK PRESS RELEASE: 09/30/10 GlaxoSmithKline (GSK) has made the decision not to pursue further worldwide development of Simplirix™ (Herpes Simplex Vaccine), an experimental vaccine intended to prevent genital herpes disease in women. The decision was made following receipt of the results of the Herpevac Trial for Women, a Phase III trial evaluating efficacy of Simplirix™, which was conducted collaboratively with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
The trial began in 2002 and 8,323 women ages 18-30 were vaccinated at 50 sites in the United States and Canada. An assessment of the final trial results showed that the vaccine had an acceptable safety profile, but the primary trial endpoint, prevention of genital herpes disease, was not met. GSK and NIH continue to evaluate data from the trial and plan to present details of the analysis in the near future in an appropriate scientific forum.
Gary Dubin, Vice President and Director, Late Clinical Development at GlaxoSmithKline Biologicals commented: “We would like to express our gratitude towards our partner NIAID for their proactive collaboration and substantial contribution in the program and the volunteers for their participation in the study.”
VRM Worldwide Autism Study
VRM: The Problem With Vaccines Part 1
VRM: The Problem With Vaccines Part 2 – Synergistic Effect of Heavy Metal Toxicity On The Body
VRM: Vaccine Clinic – A Concise Compendium To The Problem With Vaccines
VRM: The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
VRM: A Concise Compendium To The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
VRM: The Problem With Vaccines Part 4 – Primary Aspects of Vaccine Toxicity Affecting Body
VRM: The Problem With Vaccines Part 5A – Detoxification & Restoration of the Body
VRM: The Problem With Vaccines Part 5B – Detoxification & Restoration of the Body
VRM: Vaccine Ingredients
VRM: Family Charts Gradual Decline Of Daughter
VRM: Autism – Steps To Take Toward Prevention
VRM: Health Matters Part 1
VRM: Health Matters Part 2
VRM: Alternative Cancer Cures That Work
VRM: Pregnancy Tips
VRM: The Vanishing Sperm Count
VRM: Media Spin & Swine Flu Hysteria
VRM: H1N1 Vaccine Surplus From 2009 Reveals Growing Distrust of Gov’t & WHO – Cost To Taxpayers Exceeds 2.5 Billion
VRM: Flu Death Statistics – WHO & The Big Lie
VRM: Polio – United Nations & The Great Cull
VRM : Vaccine Industry Deception, Propaganda & Media Collusion
VRM: Birth of Medical & Scientific Dictatorship – Future Scenarios
VRM: H1N1 Bio-weaponry Incorporated
VRM : Aids & The WHO Connection – Criminal Intent
VRM: Morgellons Syndrome & Chemtrails
VRM : Council On Foreign Relations 10/16/09- Major Influence on Government Vaccine Policy
VRM: Closed Door CDC Meeting Reveals Industry Cover-up Of Heavy Metal Toxicity In Vaccines
VRM: The Rockefeller Foundation Drafts A Post-Pandemic Scenario
VRM : World Health Organization & Vaccine Manufacturers Implicated In Massive H1N1 Financial Scam Involving Kickbacks & Cover-ups
VRM : Former Pharmaceutical Representative Gwen Olsen Exposes Systemic Industry Fraud
VRM: Britain’s National Health Service – Criminal Syndicate Swindling Billions While Rapidly Destroying Health Care System
VRM: UK Institutes Brand of Medical Martial Law With ‘Super-Vaccination’ Day
VRM : The Awakening Has Begun
VRM: Medical Martial Law In The US – Sleeping Giant Of Tyranny
VRM : Multi-Virus Vaccine Quinvaxem Proving Deadly
VRM: New Generation Cancer Vaccine Will Cause Infertility
VRM: CDC-Gate Exposes A Trail of Fraud Behind Autism Studies
VRM : Squaline – The Military Agenda Comes Home
VRM Live – 01/28/11: Vaccine Resistance Movement founder Joel Lord discusses Synthetic Genomics, cloned cell vaccine technology & the death of natural immunity, gutter journalism & Dr. Wakefield’s imminent vindication with ‘Truth to Power’ host Paul Mabelis.
VRM Live – 11/04/10: Vaccine Resistance Movement founder Joel Lord lays out the whole vaccine process with Paul Mabelis; including heavy metal toxicity, synergy, pregnancy issues & the basic principles of natural health at risk.
VRM Live – 09/24/10: Vaccine Resistance Movement Founder Joel Lord & activist/radio host Jesse Calhoun lay it all out tonite. Topics include the VRM Worldwide Autism Study, Scientific/Medical dictatorship, Natural Rights & Vaccine Industry fraud exposed. Special thanks to host Paul Mabelis.
If you appreciate the efforts to bring this information forward do consider making a donation. Any amount, no matter how small will help enable me to carry on this invaluable research. See Paypal link on the VRM website (click on ‘Donate’ tab in upper right corner). Thank you all.